Data raises questions about long-term effects of GLP-1 therapies

Eos SENOLYTIX says new preclinical findings highlight body composition and healthy aging as the next frontier in obesity medicine.  A new set of preclinical findings from Eos SENOLYTIX is adding a longevity perspective to one of medicine’s largest and fastest-growing therapeutic areas. Presented today at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum, the data suggest […] The post Data raises questions about long-term effects of GLP-1 therapies appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.